Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Most Undervalued Stocks Under $30 to Buy

On February 25, Rick Rieder, BlackRock’s Chief Investment Officer of Global Fixed Income, joined ‘Closing Bell’ on CNBC to discuss reasons to be bullish. Reacting to reports that President Trump intends to announce further tax cuts, and despite concerns regarding the national deficit, Rieder explained that he is not surprised by initiatives aimed at maintaining economic momentum. He argued that fostering a hotter economy through tax incentives and deregulation is essential, as growth is the primary way to diffuse national debt. He emphasized the role of the Fed in this economic strategy and stated that he believes that the Fed needs to cut rates to moderate levels to support this growth-oriented environment.

Talking about whether the market is overreacting to the current angst surrounding AI spending, Rieder described the current market as one of the most fascinating yet challenging he has encountered. He suggested that humility is a vital tool for investors today, as various industries undergo rapid reevaluations. While he acknowledged that large market caps can shrink significantly as business models change, he remains generally optimistic, predicting that the economy will grow well above 5% nominal this year and that earnings growth will be solid. Additionally, he pointed out a significant technical condition that has changed: for the past few years, immense stock buybacks from hyperscalers provided a reliable backbone of support during market pressure.

That being said, we’re here with a list of the 10 most undervalued stocks under $30 to buy.

Our Methodology

We used screeners to identify stocks that are trading below a forward P/E of 15 and also below $30 per share. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Note: All data was sourced on February 26. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

10 Most Undervalued Stocks Under $30 to Buy

10. Plains GP Holdings (NASDAQ:PAGP)

Plains GP Holdings (NASDAQ:PAGP) is one of the most undervalued stocks under $30 to buy. On February 6, Plains GP reported a solid financial performance for 2025, achieving a Q4 adjusted EBITDA of $738 million and a full-year total of $2.833 billion. The company is currently undergoing a strategic transformation into a pure-play crude oil midstream provider, highlighted by the pending divestiture of its Canadian NGL business to Keyera Corp and the recent acquisition of the Cactus III pipeline.

While the NGL segment faced seasonal volatility due to warm weather, the crude oil segment remained a primary driver of stability, contributing $611 million to the final quarter’s EBITDA. For 2026, the company has set an adjusted EBITDA guidance midpoint of $2.75 billion, which accounts for the anticipated closing of the NGL sale by the end of Q1.

Management is focusing on self-help growth through efficiency initiatives aimed at $100 million in annual cost savings by 2027, with half of that targeted for 2026. Despite expectations for relatively flat Permian Basin production in the coming year, Plains GP Holdings (NASDAQ:PAGP) plans to invest ~$350 million in growth capital to integrate recent acquisitions and enhance connection programs, positioning itself for a resumption of production growth in 2027.

Plains GP Holdings (NASDAQ:PAGP), through its subsidiary, Plains All American Pipeline, owns and operates midstream infrastructure systems in the US and Canada. The company operates in two segments: Crude Oil and Natural Gas Liquids/NGLs.

9. HP Inc. (NYSE:HPQ)

HP Inc. (NYSE:HPQ) is one of the most undervalued stocks under $30 to buy. On February 24, HP reported a 7% year-over-year increase in revenue for FQ1 2026, reaching $14.4 billion. This growth was primarily fueled by the Personal Systems segment. The segment saw an 11% revenue jump and 12% unit growth, driven by a Windows 11 refresh cycle and the rising adoption of AI PCs, now accounting for over 35% of shipments. While the company achieved a non-GAAP EPS of $0.81, hitting the top of its guidance range, it faced a 2% decline in its Print segment revenue due to lower supply volumes and hardware demand.

HP is navigating significant headwinds from rising input costs, particularly for DRAM and NAND memory. These costs have surged to ~35% of the PC bill of materials, up from historical levels of 15% to 18%. Consequently, management warned that Personal Systems’ operating margins will likely remain below long-term targets for the rest of the year. To mitigate these pressures, the company is implementing pricing actions and utilizing long-term supply agreements, though it expects a volatile environment to persist into FY2027.

HP Inc. (NYSE:HPQ) maintained its full-year guidance but expects to land at the lower end of its $2.90 to $3.20 non-GAAP EPS range and its $2.8 to $3.0 billion free cash flow target. While enterprise demand remains robust in Europe and Asia, the company anticipates a double-digit decline in the TAM for PC units in CY2026 as industry-wide pricing adjustments impact consumer demand.

HP Inc. (NYSE:HPQ) provides personal computing, printing, 3D printing, hybrid work, gaming, and other related technologies in the US and internationally. The company operates through three segments: Personal Systems, Printing, and Corporate Investments.

8. Viatris Inc. (NASDAQ:VTRS)

Viatris Inc. (NASDAQ:VTRS) is one of the most undervalued stocks under $30 to buy. On February 25, Viatris announced that the FDA accepted its sNDA for MR-141, which is a phentolamine ophthalmic solution 0.75% intended to treat presbyopia. The FDA set a PDUFA goal date of October 17 this year, to complete its review. Presbyopia is a nearly universal age-related condition that affects roughly 90% of US adults over 45, causing a progressive loss of near-focusing ability and impacting approximately 128 million people domestically.

The application is supported by positive data from two pivotal Phase 3 trials, VEGA-2 and VEGA-3, which met all primary and key secondary endpoints without any treatment-related serious adverse events. Unlike some other treatments, MR-141 uses a physiological approach that relaxes the iris dilator muscle to improve near vision without affecting the ciliary muscle, thereby preserving distance vision. Detailed findings from the VEGA-3 trial are scheduled for presentation at major medical conferences in April and May of 2026.

Currently, the solution is already FDA-approved and marketed as Ryzumvi for the treatment of pharmacologically-induced mydriasis. This sNDA seeks to expand its indication to include presbyopia, providing a non-invasive option for a global market projected to reach 2.1 billion people by 2030. Viatris Inc. (NASDAQ:VTRS) holds exclusive US commercialization rights for the product through a licensing agreement with Opus Genetics.

Viatris Inc. (NASDAQ:VTRS), together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, the rest of Asia, Africa, Latin America, and the Middle East.

7. Cemex (NYSE:CX)

Cemex (NYSE:CX) is one of the most undervalued stocks under $30 to buy. On February 5, Cemex released its financial report for 2025, headlined by double-digit growth in Q4 sales and EBITDA. The company hit its $200 million recurring savings target, which helped expand margins across all regions during H2 of the year. While H1 2025 was hampered by soft demand in the US and headwinds in Mexico, the company’s full-year adjusted net income rose 41% to $1.5 billion, excluding $538 million in goodwill impairments and asset write-downs.

The company’s cash generation remained robust, with free cash flow from operations reaching $1.4 billion at a 46% conversion rate. This financial strength prompted a proposal to increase the annual cash dividend by nearly 40% to $180 million, alongside a new $500 million share buyback program spanning the next three years.

Although potential currency fluctuations and inflation pose risks, Cemex (NYSE:CX) now sees upside potential from its decarbonization efforts in Europe and a possible recovery in Mexican industrial projects following USMCA negotiations. Furthermore, energy costs per ton of cement fell by 12% in 2025, providing a favorable tailwind for sustained margin improvement in the coming year.

Cemex (NYSE:CX), together with its subsidiaries, produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and services worldwide.

6. Ecopetrol (NYSE:EC)

Ecopetrol (NYSE:EC) is one of the most undervalued stocks under $30 to buy. On February 19, Ecopetrol Group reported an increase in its proven oil and gas reserves (1P) for 2025, reaching 1.944 billion barrels of oil equivalent/mmboe. This represents a 2.7% growth compared to the previous year and the highest reserve level recorded by the company in the last four years. Despite a 13.9% drop in the average Brent reference price, the company achieved a robust reserves replacement ratio of 121%, meaning it added more resources to its portfolio than it extracted during the year.

The growth was driven by the success of enhanced recovery projects in the Castilla, Chichimene, and Akacias fields, alongside improved operational efficiency at Rubiales and La Cira–Infantas. Technical revisions and contract extensions with the ANH further supported the figures, contributing 100 mmboe to the total. As a result of these efforts, the Ecopetrol Group now maintains an average reserve life of 7.8 years, underscoring its long-term operational sustainability within a volatile market.

As Colombia’s largest integrated energy company, Ecopetrol (NYSE:EC) continues to manage over 60% of the country’s hydrocarbon production while expanding its international footprint in the Permian Basin, the Gulf of Mexico, and Brazil. Beyond oil and gas, the group maintains a diverse portfolio including energy transmission and road concessions through its majority stake in ISA.

Ecopetrol (NYSE:EC) is an integrated energy company that operates through four segments: Exploration & Production, Transport & Logistics, Refining & Petrochemicals, and Electric Power Transmission & Toll Roads Concessions.

5. NatWest Group (NYSE:NWG)

NatWest Group (NYSE:NWG) is one of the most undervalued stocks under $30 to buy. On February 13, NatWest Group delivered a standout performance in 2025, with total income rising 12% to £16.4 billion and EPS jumping 27%. The bank added 1 million new customers, leading to growth in loans, deposits, and wealth management assets. This momentum allowed the group to return £4.1 billion to shareholders through dividends and buybacks, achieving a RoTE of 19.2%.

A major highlight of the report was the acquisition of Evolent Partners, which is set to transform the bank’s wealth management profile by adding £69 billion in assets. To support its evolving business model, NatWest lowered its CET1 capital target to ~13% and updated its long-term financial goals. By 2028, the group aims to achieve a cost-to-income ratio below 45% and an RoTE greater than 18%. These targets are supported by an expected increase in structural hedge yields, which are projected to contribute billions in additional income over the next 2 years.

For 2026, NatWest Group (NYSE:NWG) expects continued growth with a total income guidance of up to £17.6 billion. While the group anticipates a slight normalization in loan impairments, management noted that there are currently no signs of consumer stress. The bank remains focused on self-help initiatives, particularly investing in AI and digital simplification to improve efficiency.

NatWest Group (NYSE:NWG), together with its subsidiaries, provides banking and financial products and services in the UK and internationally. It operates through the Retail Banking, Private Banking, and Commercial & Institutional segments.

4. América Móvil (NYSE:AMX)

América Móvil (NYSE:AMX) is one of the most undervalued stocks under $30 to buy. On February 11, América Móvil reported Q4 2025 earnings, marked by a total revenue increase to MXN 245 billion and a net profit that quadrupled compared to the previous year. The company added 2.5 million wireless subscribers during the quarter, bringing its total base to 331 million, with notable strength in the high-value postpaid segment. Additionally, fixed-line broadband saw over half a million new connections, driven by the fact that 92% of the company’s Mexican customer base is now on fiber-optic networks.

Financial efficiency was a key theme, as free cash flow surged by ~40% year-on-year to reach MXN 82 billion. This strong cash generation allowed the company to distribute MXN 45 billion to shareholders through dividends and buybacks while simultaneously reducing net debt by MXN 20 billion.

For 2026, the company plans to maintain capital expenditures at ~14% to 15% of revenue, or ~$7 billion, to support 5G expansion and fiber deployment. While América Móvil (NYSE:AMX) faced some subscriber losses in the prepaid segments of Brazil and Chile, management remains optimistic about market consolidation across Latin America.

América Móvil (NYSE:AMX) provides telecommunications services in Latin America and internationally. The company offers wireless & fixed voice services, including airtime, local, domestic, and international long-distance services, and network interconnection services.

3. Nu Holdings Ltd. (NYSE:NU)

Nu Holdings Ltd. (NYSE:NU) is one of the most undervalued stocks under $30 to buy. On February 25, Nu Holdings (or Nubank) delivered record-breaking results for 2025, closing the year with 131 million customers and an all-time high quarterly net income of $895 million. The company added 17 million customers throughout the year. Financial performance was supported by a record ROE of 33% and a significant jump in monthly average revenue per active customer/ARPAC, which rose to $15, a 27% increase over the previous year.

The company’s growth is paired with a highly efficient, low-cost operating model, maintaining a cost-to-serve of just $0.80 per active customer. In Brazil, Nu Holdings now serves 62% of the adult population, while in Mexico, it reaches 15% and has become the leading issuer of new credit cards. Asset quality also improved during the final quarter, with the 15-90 day non-performing loan ratio declining to 4.1%, supported by seasonal income boosts in the Brazilian market and disciplined risk management.

For 2026, Nu Holdings Ltd. (NYSE:NU) views the coming year as an inflection point as it transitions from a Latin American leader to a global digital banking platform. Key strategic moves include the recent conditional approval for a US national bank charter and the integration of advanced AI models like ‘nuFormer’ to enhance credit underwriting.

Nu Holdings Ltd. (NYSE:NU) provides a digital banking platform in Brazil, Mexico, Colombia, the Cayman Islands, and the US. It offers spending solutions, mobile payment solutions, and Nu Shopping.

2. Banco Bilbao Vizcaya Argentaria (NYSE:BBVA)

Banco Bilbao Vizcaya Argentaria (NYSE:BBVA) is one of the most undervalued stocks under $30 to buy. On February 5, Banco Bilbao Vizcaya Argentaria announced results for the full-year 2025, reporting a record net attributable profit of €10.5 billion, which was a 4.5% increase over the previous year. This performance was underpinned by a 16.2% growth in its loan portfolio and the acquisition of 11.5 million new customers.

Regionally, Spain and Mexico remained the primary profit engines, contributing €4.1 billion and €1.4 billion in Q4, respectively. Despite high inflation and regulatory hurdles in markets like Turkey, Banco Bilbao Vizcaya Argentaria managed to improve its efficiency ratio to 38.8% and lower its overall cost of risk to 139 basis points, reflecting a disciplined approach to credit management.

Looking toward 2026, Banco Bilbao Vizcaya Argentaria (NYSE:BBVA) aims to maintain a cost-to-income ratio below 40%, even as it continues to invest in growth franchises and AI. The bank’s mid-term strategic plan remains ambitious, targeting a total of €48 billion in profits and €36 billion in capital distributions as it leverages technology to drive long-term efficiency savings.

Banco Bilbao Vizcaya Argentaria (NYSE:BBVA), together with its subsidiaries, provides various financial services in Spain, Mexico, Turkey, South America, Europe, the US, and Asia. The company offers traditional retail, wholesale, investment, and transaction banking.

1. Pfizer Inc. (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for the first-line treatment of adults with BRAF V600E-mutant metastatic colorectal cancer/mCRC. This decision converts a previous accelerated approval into a full one, establishing the regimen as a new standard of care.

The update allows doctors to use BRAFTOVI alongside different chemotherapy options, such as mFOLFOX6 or FOLFIRI, providing more flexibility in treating this aggressive form of cancer. The approval is based on the Phase 3 BREAKWATER trial, which showed that the BRAFTOVI combination significantly improved patient outcomes compared to standard chemotherapy.

Data revealed a 51% reduction in the risk of death and a 47% reduction in the risk of disease progression. Patients receiving the BRAFTOVI and mFOLFOX6 combination saw their median overall survival double to 30.3 months, compared to 15.1 months for those on standard chemotherapy treatments. The safety profile of these combinations was consistent with previous studies of the individual drugs.

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.